News | Mammography | October 23, 2019

Cancer detection rates measure higher with DBT versus digital mammography regardless of tumor type, size or grade of cancer

Breast Tomosynthesis Increases Cancer Detection Over Digital Mammography

October 23, 2019 — Screening digital breast tomosynthesis (DBT) results in “significantly increased CDR [cancer detection rates]” compared to full-field digital mammography (FFDM), according to an ahead-of-print article in the March issue of the American Journal of Roentgenology (AJR).[1] DBT offered improved results irrespective of tumor type, size or grade of cancer.

Reviewing consecutive screening examinations performed between October 2012 and September 2014 at a large academic breast imaging practice, Pragya A. Dang, M.D., and researchers at Brigham and Women’s Hospital in Boston detected 61 cancers in the matched cohort of DBT (n = 9817) and FFDM (n = 14,180) examinations. 

CDR measured higher with DBT than with FFDM for invasive cancers (2.8 vs 1.3, p = 0.01), minimal cancers (2.4 vs 1.2, p = 0.03), estrogen receptor–positive invasive cancers (2.6 vs 1.1, p = 0.01), and node-negative invasive cancers (2.3 vs 1.1, p = 0.02.), respectively. 

However, the ratio of screen-detected invasive cancers to ductal carcinoma in situ on DBT (3.0) was not significantly different from that on FFDM (2.6) (p = 0.79).

Comparison of Overall Cancer Detection Rates of DBT and FFDM

Note—DCIS = ductal carcinoma in situ.

a —Values are rate per 1000 with number of examinations in parentheses.

b — Values in bold are statistically significant.

 

Where CDR were not statistically significant for DBT and FFDM, Dang noted, “We were likely underpowered to show a significant difference because of the smaller number of cancers in these subgroups. For instance, CDR of moderately and poorly differentiated invasive cancers, and for all cancer sizes detected with DBT, was nearly twice that of FFDM, even though it was not statistically significant.”

As Dang concluded, “our results suggest that integrating DBT into clinical practice may detect overall more cancers than does FFDM, for all tumor sub-types, grades, sizes and nodal statuses.”

For more information: www.ajronline.org

Reference

1. Dang P.A., Wang A., Senapati G.M., et al. Comparing Tumor Characteristics and Rates of Breast Cancers Detected by Screening Digital Breast Tomosynthesis and Full-Field Digital Mammography. American Journal of Roentgenology, published online Oct. 15, 2019. DOI: 10.2214/AJR.18.21060


Related Content

News | Breast Imaging

Aug. 13, 2026 – Perimeter Medical Imaging AI recently announced that Intermountain Health, the largest nonprofit health ...

Time August 14, 2026
arrow
News | Breast Imaging

Aug. 3, 2026 — QT Imaging Holdings, is advancing the direct U.S. commercial strategy for its Breast Acoustic CT Scanner ...

Time August 04, 2026
arrow
News | Breast Imaging

Aug. 3, 2026 — GE HealthCare has launched Invenia ABUS (Automated Breast Ultrasound) Prime and ABUS StreamVue, a ...

Time August 03, 2026
arrow
News | Breast Imaging

July 30, 2026 — DeepHealth, Inc. has received FDA 510(k) clearance for DeepHealth Breast Ultrasound1, an AI-powered ...

Time July 31, 2026
arrow
News | Computed Tomography (CT)

July 23, 2026 — HOPPR has introduced HOPPR EF Chest CT Narrative Model, a foundation model that processes 3D chest CT ...

Time July 27, 2026
arrow
News | PET Imaging

July 14, 2026 — New research is shedding new light on the biological basis of schizophrenia by directly measuring ...

Time July 15, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

July 7, 2026 — Imagion Biosystems, Ltd. recently announced it has renewed and extended its collaboration agreement with ...

Time July 07, 2026
arrow
News | Breast Imaging

July 7, 2026 — QT Imaging Holdings, Inc. recently announced it has successfully completed its first routine inspection ...

Time July 07, 2026
arrow
News | MRI Breast

July 2, 2026 – Quibim has announced the European and UK launch of QP-Breast, its CE and UKCA-marked AI tool which ...

Time July 02, 2026
arrow
News | Mammography

June 30, 2026 — The Food and Drug Administration has cleared new contrast-enhanced mammography (CEM) and CEM biopsy ...

Time June 30, 2026
arrow
Subscribe Now